Business Context and Reporting Period
This Form 8-K, dated October 1, 2018, reports on Akebia Therapeutics, Inc. (Akebia), a Delaware corporation. The filing details the entry into a material definitive agreement regarding a proposed merger with Keryx Biopharmaceuticals, Inc. (Keryx).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a corporate transaction.
Material Changes and Transaction Details
On October 1, 2018, Akebia entered into the First Amendment to the Agreement and Plan of Merger originally dated June 28, 2018. The key modification concerns the composition of the Akebia Board of Directors following the merger:
- Board Size: The board will increase to ten (10) directors at the effective time of the merger.
- Composition:
- Four (4) Continuing Directors designated by the Akebia Board.
- Five (5) Keryx Board Designees designated by the Keryx Board.
- One (1) Additional Independent Director designated jointly, who will serve as Chairperson.
- Class Allocation: Directors are allocated into three classes for staggered re-election:
- Class II (2019): 1 Continuing Director, 2 Keryx Designees.
- Class III (2020): 1 Additional Director, 1 Continuing Director, 1 Keryx Designee.
- Class I (2021): 2 Continuing Directors, 2 Keryx Designees.
The remainder of the original Merger Agreement remains in full force and effect.
Guidance, Outlook, and Risks
Outlook and Next Steps: Akebia and Keryx plan to file a joint proxy statement/prospectus with the SEC for shareholder review and voting. The transaction is subject to satisfaction or waiver of closing conditions, including stockholder approval and regulatory approvals.
Risks and Contingencies: The filing highlights significant risks that could prevent the merger from closing or alter its benefits, including:
- Failure to obtain required stockholder or governmental approvals.
- Unexpected costs, liabilities, or delays.
- Disruption of operations, management attention, and employee retention.
- Adverse effects on business relationships with customers and suppliers.
- Legal proceedings related to the merger.
Investor Verification Checklist
- Verify the final terms of the merger in the upcoming joint proxy statement/prospectus.
- Confirm the specific names of the designated directors and the Additional Independent Director.
- Monitor the status of regulatory approvals and stockholder voting results.
- Review the most recent Form 10-Q filings for both Akebia and Keryx for detailed risk factors and financial conditions.
- Check for any subsequent Form 4 filings regarding changes in ownership by directors and officers.